BioCentury | Mar 21, 2017
Distillery Therapeutics

Pulmonary

...Pharma Corp. market Daliresp roflumilast, a PDE-4 inhibitor, to treat COPD. Chiesi Farmaceutici S.p.A. has CHF 6001...
BioCentury | Oct 29, 2012
Clinical News

CHF 6001: Phase I data

...74 healthy volunteers showed that single and repeated ascending-doses of up to 2,000 µg inhaled CHF 6001...
...side effects. No relevant safety findings, including cardiac side effects, were observed. Chiesi is evaluating CHF 6001...
...asthma and chronic obstructive pulmonary disease (COPD), respectively. Chiesi Farmaceutici S.p.A. , Parma, Italy Product: CHF 6001...
Items per page:
1 - 2 of 2